Semaphorin3A Rewires CD4+ T-Cell Metabolism via AKT/mTORC1 Inhibition in Health and Rheumatoid Arthritis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262211160 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Raeda Mubariki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Proteomic Unit, Bnai Zion Medical Center, Haifa 3478403, Israel. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Semaphorin-3A, Mechanistic Target of Rapamycin Complex 1, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Semaphorin3A (Sema3A) is a regulatory protein found to be expressed on regulatory T and B cells and also secreted into peripheral blood. It has been identified as a potent immune regulator; however, not all its regulatory mechanisms have been evaluated. In this respect, we aim to investigate how Sema3A affects key metabolic pathways in T cells during homeostasis and rheumatoid arthritis (RA), and on the AKT/mTORC1 signaling axis. In this study, peripheral blood samples were collected from 119 healthy donors and 32 rheumatoid arthritis patients. T cells were subjected to Seahorse analysis to evaluate OXPHOS and glycolysis, live cell TMRE staining to evaluate mitochondrial activity, mass spectrometry for metabolite profiling, ATP determination to study ATP production, and Western blot analysis to investigate the signaling pathway activity. This study presents evidence showing that Sema3A inhibits the AKT/mTORC1 pathway, leading to a decreased glucose uptake and glycolysis disruption. Furthermore, we show that Sema3A reduces mitochondrial capacity and OXPHOS in activated T cells of healthy and RA donors, leading to a decreased ATP production. In contrast, Sema3A upregulates fatty acid oxidation (FA), probably as a backup pathway to ensure cell survival. Results with p values of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Proteomic Unit, Bnai Zion Medical Center, Haifa 3478403, Israel.
- Rappaport Faculty of Medicine, Technion, Haifa 3478403, Israel.
- Rheumatology Unit, Bnai Zion Medical Center, Haifa 3478403, Israel.
- Rheumatology Out-Patient Clinic, "Lin"-Clalit Health Services (OMG), Haifa 3478403, Israel.
ORCID-Profile: Devy Zisman
Zitieren
APA
Mubariki, R., Eiza, N., Sabag, A. D., Keret, S., Rimar, D., Slobodin, G., Zisman, D., Toubi, E., & Vadasz, Z. (2025). Semaphorin3A Rewires CD4+ T-Cell Metabolism via AKT/mTORC1 Inhibition in Health and Rheumatoid Arthritis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262211160
Vancouver
Mubariki R, Eiza N, Sabag AD, Keret S, Rimar D, Slobodin G, et al. Semaphorin3A Rewires CD4+ T-Cell Metabolism via AKT/mTORC1 Inhibition in Health and Rheumatoid Arthritis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262211160
BibTeX
@article{Mubariki2025,
author = {Mubariki, Raeda and Eiza, Nasren and Sabag, Adi D and Keret, Shiri and Rimar, Doron and Slobodin, Gleb and Zisman, Devy and Toubi, Elias and Vadasz, Zahava},
title = {Semaphorin3A Rewires CD4+ T-Cell Metabolism via AKT/mTORC1 Inhibition in Health and Rheumatoid Arthritis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262211160}
}
EUVIMED